Skip to content

The Molecular Pathogenesis Study of Cataract

The Molecular Pathogenesis Study of Cataract

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05682001
Enrollment
150
Registered
2023-01-12
Start date
2022-01-01
Completion date
2025-12-30
Last updated
2023-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract, Pathogenesis

Brief summary

To study the molecular pathogenesis of cataract and explore possible treatments,anterior lens capsules were collected from cataract patients

Detailed description

Anterior lens capsules were collected from the patients with DC and ARC, and transparent crystals of cadaveric eyes. M6A epitranscriptomic microarray was performed to investigate the altered m6A modifications and determine the differentially expressed mRNAs. The potential role of dysregulated m6A modification levels was predicted through Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. Real-time polymerase chain reaction was performed to identify the dysregulated expression of RNA methyltransferases, demethylases, and readers.

Interventions

None listed

Sponsors

National Natural Science Foundation of China
CollaboratorOTHER_GOV
Eye & ENT Hospital of Fudan University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* diabetic cataract * underwent cataract surgery

Exclusion criteria

* Combined with other eye diseases * underwent other eye surgery

Design outcomes

Primary

MeasureTime frameDescription
m6A modification of mRNAs1 monthEpitranscriptomic microarray analysis reveals the differential m6A modification of mRNAs in DC samples
expression level of mRNAs1 monththe m6A microarray analyses provide data for mRNA expression levels
levels of methylated mRNA1 monthin vitro validation of the diverse expression levels of methylated mRNA
levels of RNA methyltransferase1 monthin vitro validation of the diverse expression levels of RNA methyltransferase

Countries

China

Contacts

Primary ContactLei Cai, MD
clyc0318@126.com13816956828

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026